Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
ASDA's leadership is facing challenges after a staff survey showed that less than half of the workers are confident in the supermarket's long-term plan.
The survey, completed by 75,591 employees last month, revealed that only 47 per cent of respondents believe in the supermarket chain's strategic direction, the Telegraph reported.
Additionally, just 48 per cent of workers felt they could explain the benefits of Asda’s "Future Programme," which involves transitioning IT systems from former owner Walmart.
This change, overseen by co-owner Mohsin Issa, has encountered problems, including incorrect pay for thousands of staff, leaving some without enough money and others having to repay the supermarket.
Asda acknowledged these "short-term challenges." In the survey, however, 50 per cent of employees expressed confidence that the company would address the issues raised.
According to the report, the survey results added pressure on Asda's leadership to improve their turnaround strategy amid ongoing staff dissatisfaction and a decline in market share.
CEO Mohsin Issa has been trying to revitalise the supermarket by overhauling management and bringing in new executives like Iceland’s group buying director Andrew Staniland.
Despite these efforts, data from consumer intelligence firm NIQ showed a 5.9 per cent drop in sales for the 12 weeks leading up to July 13 compared to the previous year, making Asda the only major supermarket with declining sales.
Marketing data and analytics company Kantar's figures indicated that Asda's market share has decreased to 12.7 per cent from 14.8 per cent since Issa and his partners acquired the company in 2021.
MPs have questioned whether cost-cutting measures are affecting Asda's competitiveness. The supermarket insists it is reinvesting in the business, upgrading stores, and increasing staff.
Union leaders, including GMB national officer Nadine Houghton, were not surprised by the survey results. Houghton criticised Asda's lack of a clear strategy, noting the supermarket's loss of market share, the departure of senior staff, and the ongoing search for a new CEO.
Asda has been looking for a replacement for Mohsin Issa, who has managed the supermarket since 2021, offering a pay package of between £8 million and £10m for the role.
An Asda spokesman said the company is conducting an "extensive international search" for a permanent CEO and is committed to finding the best candidate.
The spokesman added that Asda regularly updates the GMB on various topics, including future investment plans, and values direct feedback from the survey, which allows employees to share their honest opinions.
Asda's overall engagement score, which measures pride, advocacy, and commitment among employees, exceeded 70 per cent. However, the company acknowledges areas needing improvement and is focused on addressing these issues.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.